July 26, 2016 2:34 PM ET


Company Overview of VaxInnate Corporation

Company Overview

VaxInnate Corporation, a biotechnology company, provides a technology that involves genetically fusing vaccine antigens to the bacterial protein flagellin, a potent stimulator of the innate immune system. The company’s technology platform is based on proprietary toll-like receptor technology, which potentiates the immune response. Its vaccines focus on infectious diseases, including seasonal and pandemic influenza, clostridium difficile, and dengue. VaxInnate Corporation was incorporated in 2001 and is headquartered in Cranbury, New Jersey.

3 Cedar Brook Drive

Suite 1

Cranbury, NJ 08512

United States

Founded in 2001





Key Executives for VaxInnate Corporation

Chief Executive Officer, President and Director
Age: 61
Scientific Founder
Chief Financial Officer
Age: 55
Vice President of Business Development
Age: 57
Compensation as of Fiscal Year 2016.

VaxInnate Corporation Key Developments

VaxInnate Corporation Presents at ChinaBio Partnering Forum 2016, May-18-2016

VaxInnate Corporation Presents at ChinaBio Partnering Forum 2016, May-18-2016 . Venue: Suzhou, China.

VaxInnate, Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 10:45 AM

VaxInnate, Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 10:45 AM. Venue: Le Parker Meridien Hotel, 119 W. 56th Street, New York, NY 10019, United States. Speakers: Wayne F. Pisano, Chief Executive Officer, President and Director.

VaxInnate Corporation Appoints Thomas P. Monath to Board of Directors

VaxInnate Corporation announced the appointment of Thomas P. Monath, MD to the Company's board of directors. Dr. Monath is an internationally known virologist and vaccinologist with significant experience in the biotechnology industry and at the Centers for Disease Control and Prevention (CDC). Dr. Monath currently serves as the chief scientific and chief operating officer of BioProtection Systems, a subsidiary of NewLink Genetics Corporation, where he is leading the development of an Ebola virus vaccine in partnership with Merck. Prior to joining NewLink, Tom held various industry roles at PaxVax Inc., Hookipa Biotech AG, Juvaris Inc., Xcellerex Inc. and Acambis Inc. prior to its acquisition by Sanofi Pasteur. In these roles, he was involved in the development of a broad array of vaccines including those for cholera, influenza, polio, malaria, HIV, anthrax, dengue, Japanese encephalitis, West Nile, yellow fever, Clostridium difficile and smallpox.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Private Placement
September 18, 2015

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact VaxInnate Corporation, please visit vaxinnate.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.